Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al.
Harter P (1), Reuss A, Sehouli J, Chiva L, du Bois A.
1*Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen; †Coordinating Center for Clinical Trials, Philipps-University Marburg, Marburg; ‡Department of Gynecology, Charité, Berlin, Germany; and §Department of Gynecology Oncology, MD Anderson Cancer Center, Madrid, Spain.
With great interest, we read the publication about the first published randomized trial regarding Hyperthermic intraperitoneal chemotherapy (HIPEC) ‘‘Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study’’ by Spiliotis et al published in Annals of Surgical Oncology.
The authors report a benefit regarding mean survival for the use of HIPEC in addition to cytoreductive surgery in patients with recurrent ovarian cancer.
This was the first randomized trial for this new treatment modality and has potential to change clinical practice. Therefore, thorough critical discussion is of clinical and scientific importance.
CITATION Int J Gynecol Cancer. 2017 Feb;27(2):246-247. doi: 10.1097/IGC.0000000000000864